234 related articles for article (PubMed ID: 21619605)
1. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.
Tieszen CR; Goyeneche AA; Brandhagen BN; Ortbahn CT; Telleria CM
BMC Cancer; 2011 May; 11():207. PubMed ID: 21619605
[TBL] [Abstract][Full Text] [Related]
2. Response of human ovarian carcinoma cell lines to antiprogestin mifepristone.
Rose FV; Barnea ER
Oncogene; 1996 Mar; 12(5):999-1003. PubMed ID: 8649817
[TBL] [Abstract][Full Text] [Related]
3. Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells.
Gaddy VT; Barrett JT; Delk JN; Kallab AM; Porter AG; Schoenlein PV
Clin Cancer Res; 2004 Aug; 10(15):5215-25. PubMed ID: 15297425
[TBL] [Abstract][Full Text] [Related]
4. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2.
Goyeneche AA; Seidel EE; Telleria CM
Invest New Drugs; 2012 Jun; 30(3):967-80. PubMed ID: 21424700
[TBL] [Abstract][Full Text] [Related]
5. Cytostasis and morphological changes induced by mifepristone in human metastatic cancer cells involve cytoskeletal filamentous actin reorganization and impairment of cell adhesion dynamics.
Brandhagen BN; Tieszen CR; Ulmer TM; Tracy MS; Goyeneche AA; Telleria CM
BMC Cancer; 2013 Jan; 13():35. PubMed ID: 23351358
[TBL] [Abstract][Full Text] [Related]
6. Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
Rojas PA; May M; Sequeira GR; Elia A; Alvarez M; Martínez P; Gonzalez P; Hewitt S; He X; Perou CM; Molinolo A; Gibbons L; Abba MC; Gass H; Lanari C
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376177
[TBL] [Abstract][Full Text] [Related]
7. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.
Goyeneche AA; Carón RW; Telleria CM
Clin Cancer Res; 2007 Jun; 13(11):3370-9. PubMed ID: 17545545
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity.
Gamarra-Luques CD; Hapon MB; Goyeneche AA; Telleria CM
J Ovarian Res; 2014; 7():45. PubMed ID: 24795781
[TBL] [Abstract][Full Text] [Related]
9. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
Wargon V; Riggio M; Giulianelli S; Sequeira GR; Rojas P; May M; Polo ML; Gorostiaga MA; Jacobsen B; Molinolo A; Novaro V; Lanari C
Int J Cancer; 2015 Jun; 136(11):2680-92. PubMed ID: 25363551
[TBL] [Abstract][Full Text] [Related]
10. Anticancer effects of mifepristone on human uveal melanoma cells.
Alvarez PB; Laskaris A; Goyeneche AA; Chen Y; Telleria CM; Burnier JV
Cancer Cell Int; 2021 Nov; 21(1):607. PubMed ID: 34789240
[TBL] [Abstract][Full Text] [Related]
11. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA
Ponandai-Srinivasan S; Lalitkumar PG; Garcia L; Varghese SJ; Carlson JW; Gemzell-Danielsson K; Floter Radestad A
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):250-261. PubMed ID: 30325501
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties.
Afhüppe W; Beekman JM; Otto C; Korr D; Hoffmann J; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2010 Mar; 119(1-2):45-55. PubMed ID: 20043998
[TBL] [Abstract][Full Text] [Related]
13. Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment.
Freeburg EM; Goyeneche AA; Telleria CM
Int J Oncol; 2009 Mar; 34(3):743-55. PubMed ID: 19212679
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas.
Montecchia MF; Lamb C; Molinolo AA; Luthy IA; Pazos P; Charreau E; Vanzulli S; Lanari C
J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):11-21. PubMed ID: 10215033
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression.
Ponikwicka-Tyszko D; Chrusciel M; Stelmaszewska J; Bernaczyk P; Chrusciel P; Sztachelska M; Scheinin M; Bidzinski M; Szamatowicz J; Huhtaniemi IT; Wolczynski S; Rahman NA
EBioMedicine; 2019 Sep; 47():170-183. PubMed ID: 31466918
[TBL] [Abstract][Full Text] [Related]
16. Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.
Gamarra-Luques CD; Goyeneche AA; Hapon MB; Telleria CM
BMC Cancer; 2012 Jun; 12():200. PubMed ID: 22642877
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line.
Thomas M; Monet JD
J Clin Endocrinol Metab; 1992 Sep; 75(3):865-70. PubMed ID: 1517379
[TBL] [Abstract][Full Text] [Related]
18. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells.
Classen S; Possinger K; Pelka-Fleischer R; Wilmanns W
J Steroid Biochem Mol Biol; 1993 Apr; 45(4):315-9. PubMed ID: 8499339
[TBL] [Abstract][Full Text] [Related]
19. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV
Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686
[TBL] [Abstract][Full Text] [Related]
20. Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21.
Musgrove EA; Lee CS; Cornish AL; Swarbrick A; Sutherland RL
Mol Endocrinol; 1997 Jan; 11(1):54-66. PubMed ID: 8994188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
